Showing 6101-6110 of 8203 results for "".
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Platelet-Rich Plasma Improves Outcomes in Severe ADhttps://practicaldermatology.com/news/platelet-rich-plasma-improves-outcomes-severe-ad/2467268/A new study looking at platelet-rich plasma (PRP) as an adjuvant therapy for adult atopic dermatitis (AD) suggested the treatment was associated with favorable outcomes. The literature search focused on original English-language articles about PRP as a therapeutic method for adult AD. Revi
- Study: 5-mm Margins Adequate for Small Melanoma in Situ Lesionshttps://practicaldermatology.com/news/study-5-mm-margins-adequate-small-mis-lesions/2467262/New research shed light on the recurrence rates of melanoma in situ (MIS) lesions removed with a 5-mm margin. "The incidence of MIS has increased significantly over the past decades, and traditional guidelines for treatment of MIS have been excision with a 5-mm clinical margin; however, c
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and
- NEA Study Illuminates Gaps in Mental Health Help for Eczema Patientshttps://practicaldermatology.com/news/nea-study-illuminates-gaps-mental-health-help-eczema-patients/2467195/Forty-two percent of patients with atopic dermatitis (eczema) and caregivers of children/teens with the condition never spoke about mental health with primary eczema care providers, according to National Eczema Association (NEA
- POSITIVE: Tildrakizumab Shows Effectiveness in Psoriasis Patients at 52 Weekshttps://practicaldermatology.com/news/positive-tildrakizumab-shows-effectiveness-psoriasis-patients-52-weeks/2467194/New one-year data presented at the International Federation of Psoriasis Associations (IFPA) Conference 2024 showed that tildrakizumab (Illumetri, Almirall) was effective at restoring and maintaining wellbeing of patients with moderate-to-severe psoriasis. Researchers for the POSITIVE st
- Erenumab Associated with Reduced Rosacea-associated Flushing, Chronic Erythemahttps://practicaldermatology.com/news/erenumab-associated-reduced-rosacea-associated-flushing-chronic-erythema/2467166/Erenumab, an anti–calcitonin gene-related peptide (CGRP)-receptor monoclonal antibody, was shown in new research to be effective at reducing the number of days with rosacea-associated erythema and flushing in treated patients.